U.S. FOOD & DRUG ADMINISTRATION

# Role of Computational Fluid Dynamics and Physiologically-Based Pharmacokinetic Modeling in Development of Orally Inhaled and Nasal Drug Products

## University of Texas-El Paso (UTEP) Student Seminar

May 11, 2020

**Ross Walenga, Ph.D.**
Chemical Engineer
Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs
CDER | US FDA

# Speaker Disclaimer

The opinions and conclusions expressed in this forum are the viewpoints of the speaker(s) and do not necessarily reflect the official position of the U.S. Food and Drug Administration.

Reference to any marketed products is for illustrative purposes only and does not constitute endorsement by the U.S. Government, the Department of Health and Human Services, or the Food and Drug Administration.

# Orally Inhaled and Nasal Drug Products (OINDPs)

- Orally Inhaled
  - Metered dose inhalers (MDIs)
  - Dry powder inhalers (DPIs)
  - Nebulizers
- Nasal
  - Nasal sprays
  - Nasal metered aerosols

www.webmd.com

https://www.advairhcp.com/

www.sasrx.com

www.wellrx.com

# NDA vs. ANDA Review Process

| New Drug<br>NDA Requirements | Generic Drug<br>ANDA Requirements |
|---|---|
| 1. Chemistry | 1. Chemistry |
| 2. Manufacturing | 2. Manufacturing |
| 3. Controls | 3. Controls |
| 4. Microbiology | 4. Microbiology |
| 5. Biopharmaceutics | 5. Biopharmaceutics |
| 6. Preclinical Studies | |
| 7. Clin. Pharm. | 6. Bioequivalence (BE) |
| 8. Clinical Studies | |



ANDA: abbreviated new drug application; NDA: new drug application

# Products Delivered to the Respiratory System

- Factors influencing patient-product interactions and drug bioavailability include:
  - Dose percent deposited to nasal mucosa, or in the lungs vs. dose percent swallowed and absorbed from the GI tract
  - Local solubility/permeability
  - Receptor affinity
  - Deposition in central vs. peripheral parts of the pulmonary tree
  - Pulmonary residence time
  - Local clearance (mucociliary transport and reticuloendothelial uptake)
  - Device design
  - Effects of formulation differences on product differences



Slide adapted from Dr. Kimberly Witzmann

# Generic Drug User Fee Amendments (GDUFA)

- Passed in July 2012 to speed access to safe and effective generic drugs to the public, reauthorized in 2017
- Requires user fees to supplement costs of reviewing generic drug applications and provides additional resources, including support for **regulatory science research**
- User fee program which directly supports regulatory science research activities
  - https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/genericdrugs/ucm567695.htm



Slide adapted from Dr. Kimberly Witzmann

# Computational Fluid Dynamics (CFD) Modeling of OINDPs

- Predict influence of device and formulation parameters
  - Particle size distribution
  - Regional deposition
    - Intersubject variability
  - Pharmacokinetic (PK) profile
    - Combined with physiologically-based pharmacokinetic (PBPK) modeling




Flow streamlines in non-spiral and spiral versions of ACTIVAIR® dry powder inhaler. (Fig. 6 from Lee et al. (2018))

# Device Modification to Match In Vitro Performance

- Research funded by the Office of Generic Drugs (OGD)
  - University of Bath (PI: Jagdeep Shur)
- Two capsule-based dry powder inhalers (DPIs) with tiotropium bromide - Handihaler® and Cyclohaler®
- Model flow and particle transport using CFD
- Modify Cyclohaler® to achieve comparable predictions
- Compare in vitro particle size distribution




Computer aided design (CAD) representations of a) Handihaler® and b) Cyclohaler®. Fig.1 from Shur et al. (2012)

# Velocity Comparison Following Device Modification




CFD Predictions in unmodified Cyclohaler® for a) device pressure, b) device velocity, and c) capsule pressure. (Fig 3. from Shur et al. (2012))




CFD predictions of Cyclohaler® device pressure in a) modification #1, and b) modification #2. (Fig. 4 from Shur et al. (2012))

# In Vitro Particle Size Distribution Comparison




Stage measurements in Next Generation Impactor for Handihaler®, Cyclohaler®, and two modifications of Cyclohaler® for flow rate of 20 L/min. Abbreviations: mouthpiece (MP), throat (T), and preseparator (PS). (Fig. 6a from Shur et al. (2012))

# Regional Deposition Intersubject Variability




CFD predictions of particle deposition locations in left lower lobe, from Choi et al. (2017)

- GDUFA funded research
  - University of Iowa (PI: Ching-Long Lin)
- Cluster-based approach
  - Asthma patient sub-types
  - Computed tomography (CT) scans from database
- Generate 10 lung models
  - Male and female for healthy and four hypothesized sub-types

# Nasal Absorption Model Using CFD

- GDUFA funded research
  - Virginia Commonwealth University (PI: P. Worth Longest)
- Predict local delivery of nasal suspension spray droplet using CFD
- Predict mucociliary transit and dissolution using CFD with 2D surface model




Nasal absorption process, with a) CFD prediction of deposition, b) mucociliary transit model, and c) dissolution, advection, and absorption model. (Fig.1 from Rygg et al. (2016))

# Connection of Nasal Absorption and PK




Two-compartment pharmacokinetic (PK) model structure. (Fig. 4 from Rygg et al. (2016b)




Pharmacokinetic (PK) profile prediction as compared with in vivo data from Daley-Yates et al. (), as well as comparison of bioavailability (F). The inset bar-graph shows distance of drug deposited from nostril in either the nasal vestibule (NV) or the middle passage (MP). (Fig. 6 from Rygg et al. (2016b)

# CFD and PBPK for Nasal Products

- GDUFA funded research
  - Applied Research Associates (PI: Jeffry Schroeter)
- Fully 3D CFD model predicts deposition
- Physiologically-based pharmacokinetic (PBPK) model for nasal absorption
- Investigation of device and usage parameters




CFD predictions for deposition locations of fluticasone propionate droplets, from Kimbell et al. (2017)




Pharmacokinetic (PK) predictions of fluticasone propionate nasal spray, from of Schroeter et al. (2017)

# Quasi-3D CFD Model for Lung Absorption

- GDUFA funded research
  - CFD Research Corporation (PI: Narender Singh)
- Fully 3D CFD model to predict regional deposition
- Quasi-3D model to predict mucociliary transit, dissolution, absorption
- Coupled with PBPK model




Local drug concentration predictions of solid and dissolved fluticasone propionate Fig. 15 from Kannan et al. (2018)

# New GDUFA Funded Research

- CFD modeling combined with discrete element modeling (DEM) to predict drug-carrier particle interactions of DPIs
  - Princeton University (PI: Jari Kolehmainen)
  - University of Sydney (PI: Kim Chan)
- Fully 3D CFD nasal mucociliary clearance model to allow for local concentration predictions
  - North Carolina State University (PI: Clement Kleinstreuer)

# New GDUFA Funded Research (cont'd)

- Further development of quasi-3D model for lung absorption
  - CFD Research Corporation (PI: Narender Singh)
- Nasal in vitro model development that characterizes intersubject variability of nasal spray deposition, supported by CFD predictions
  - Virginia Commonwealth University (PI: Laleh Golshahi)

# Internal GDUFA Funded Research

- CFD models of droplet formulation from metered dose inhaler (MDI)
- CFD models of OINDPs based on Respimat® device
- Development of CFD-PBPK models for opioid nasal insufflation for assessment of abuse deterrence

# Conclusions

- Development of OINDPs is challenging due to the need for multiple device and formulation changes without knowledge of their impact.
- CFD may be used to predict the influence of device and formulation changes on metrics of interest, including particle size distribution, PK, and drug concentration at the site of action.
- Intersubject variability may be examined using CFD with several realistic lung models from a given population.
- It is expected that when CFD is used concurrently with OINDP development, the process will be more effective and efficient.

# Acknowledgements


- FDA/CDER/OGD/ORS
  - Andrew Babiskin
  - Kimberly Witzmann
  - Myong-Jin Kim
  - Liang Zhao
  - Lei Zhang
  - Robert Lionberger
- FDA/CDER/OPQ/ONDP
  - Renishkumar Delvadia
- FDA/CDER/OPQ/SS
  - Geng Tian
- FDA/CDER/OTS/OCP
  - Bhawana Saluja
- FDA/CDRH/OIR/DRH
  - Alex Rygg
- University of Bath
  - Jagdeep Shur
- Virginia Commonwealth University
  - P. Worth Longest
- Applied Research Associates, Inc.
  - Jeffrey Schroeter
- CFD Research Corporation
  - Narender Singh
  - Ravi Kannan
  - Andrzej Przekwas
- University of North Carolina
  - Julie Kimbell

FDA
U.S. FOOD & DRUG
ADMINISTRATION

# References


- Lee HJ, Kwon IH, Lee HG, Kwon YB, Woo HM, Cho SM, Choi YW, Chon J, Kim K, Kim DW, Park CW. Spiral mouthpiece design in a dry powder inhaler to improve aerosolization. International journal of pharmaceutics. 2018;553(1-2):149-56.
- Shur J, Lee S, Adams W, Lionberger R, Tibbatts J, Price R. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers. The AAPS journal. 2012;14(4):667-76.
- Choi J, LeBlanc LJ, Choi S, Haghighi B, Hoffman EA, O'Shaughnessy P, Wenzel SE, Castro M, Fain S, Jarjour N, Schiebler ML, Denlinger L, Lin C-L. Characteristics of inhaled particle deposition in the lungs of imaging-based asthma clusters: A numerical study. American Thoracic Society (ATS) 2018 (May 18-23, 2018), San Diego, California, United States.
- Rygg A, Hindle M, Longest PW. Absorption and clearance of pharmaceutical aerosols in the human nose: effects of nasal spray suspension particle size and properties. Pharmaceutical research. 2016;33(4):909-21.
- Rygg A, Hindle M, Longest PW. Linking suspension nasal spray drug deposition patterns to pharmacokinetic profiles: a proof-of-concept study using computational fluid dynamics. Journal of pharmaceutical sciences. 2016;105(6):1995-2004.

# References (cont'd)


- Kimbell J, Schroeter J, Tian G, Walenga R, Babiskin A, Delvadia R. Estimating size-specific numbers of active pharmaceutical ingredient particles in the regional deposition of a nasal spray. J Aerosol Med Pulm Drug Deliv. 2017;30(3):18-19.
- Schroeter J, Kimbell J, Walenga R, Babiskin A, Delvadia R. A CFD-PBPK model to simulate nasal absorption and systemic bioavailability of intranasal fluticasone propionate. J Aerosol Med Pulm Drug Deliv. 2017;30(3):13-14 Bonsmann U, Bachert C, Delank KW, Rohdewald P. Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application. Allergy. 2001;56(6):532-5.
- Kannan RR, Singh N, Przekwas A. A Compartment-Quasi3D multiscale approach for drug absorption, transport, and retention in the human lungs. International journal for numerical methods in biomedical engineering. 2018;34(5):e2955.